MarketCapExport financials
Evolent Health (EVH)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Evolent Health Income Statement 2025-2011 | EVH
Brief overview of income trends at Evolent Health
The figures are compared over a five-year interval. Revenue reported by Evolent Health was $925 million at the beginning of the period and $469 million at the end. Overall revenue changed by −49.3%, equal to an annualized rate of about −12.7%. The business finished the period with a smaller revenue base.
Gross profit changed from 228 million dollars to −1 billion dollars (−541.8%). Direct costs outpaced revenue, limiting the benefit of changes in sales. Gross margin moved from 24.7% to −215%. Weakening gross profitability reduces the quality of the top-line trend.
EBITDA changed from −$201 million to −$294 million (−46.1%). Operating performance was consistent with the change in sales. Comparing the endpoints gives EBITDA margins of −21.8% and −62.8%. A lower EBITDA share weakens the quality of the result.
Net income moved from −334 million dollars at the start to −579 million dollars at the end. Profitability deteriorated further over the five years.
Over the period, capitalization shifted from $1.7 billion to $865 million (−49.5%). The decline in value indicates softer investor confidence.
Financial takeaway
Signs of deterioration dominate the five-year picture. The weaker side of the profile includes weaker operating efficiency, declining net profitability and a narrow gross-profit buffer. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Evolent Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
865 M | 2.41 B | 3.32 B | 3.28 B | 2.29 B | 1.71 B | 866 M | 1.33 B | 914 M | 820 M | 248 M | - | - | - | - |
Shares |
114 M | 115 M | 111 M | 93.7 M | 86.1 M | 84.9 M | 82.4 M | 77.3 M | 64.4 M | 45 M | 25.1 M | - | - | - | - |
Historical Prices |
7.57 | 21 | 29.8 | 35 | 26.6 | 20.1 | 9.24 | 13.2 | 14.7 | 19.7 | 10.1 | - | - | - | - |
Net Income |
-579 M | -93.5 M | -142 M | -19.2 M | -37.6 M | -334 M | -302 M | -52.7 M | -60.7 M | -160 M | 332 M | -25.2 M | 20 M | - | - |
Revenue |
469 M | 647 M | 556 M | 382 M | 248 M | 247 M | 846 M | 627 M | 435 M | 254 M | 96.9 M | - | 25.7 M | - | - |
Cost of Revenue |
1.48 B | 2.19 B | 1.5 B | 1.04 B | 658 M | 697 M | - | - | - | - | - | - | - | - | - |
Gross Profit |
-1.01 B | -1.54 B | -947 M | -653 M | -409 M | -450 M | 333 M | 299 M | 166 M | 99 M | 39.5 M | - | -4.35 M | - | - |
Operating Income |
-410 M | -40.5 M | -71.2 M | 3.64 M | -42.4 M | -263 M | -309 M | -47.5 M | -72.8 M | -237 M | -43 M | - | -21.2 M | - | - |
Interest Expense |
249 K | 241 K | 54.2 M | 15.6 M | 25.4 M | 28.3 M | 14.6 M | 5.48 M | 3.64 M | 247 K | - | - | -820 K | - | - |
EBITDA |
-294 M | 77.9 M | 52.2 M | 70.8 M | 17.6 M | -201 M | -59.5 M | -7.07 M | -40.1 M | -61.7 M | -35.8 M | - | -19.9 M | - | - |
Operating Expenses |
-597 M | -1.5 B | 577 M | 384 M | 261 M | 247 M | 454 M | 351 M | 238 M | 178 M | 82.5 M | - | 16.8 M | - | - |
General and Administrative Expenses |
304 M | 263 M | 358 M | 269 M | 219 M | 210 M | 393 M | 306 M | 206 M | 161 M | 75.3 M | - | 15.6 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Evolent Health
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
113 M | 113 M | 112 M | -875 K | 114 M | 116 M | 115 M | 117 M | 115 M | 115 M | 114 M | 787 K | 112 M | 111 M | 108 M | 2.06 M | 95.3 M | 90.1 M | 89.5 M | 761 K | 85.8 M | 85.4 M | 84.7 M | 2.31 M | 85.2 M | 85.3 M | 84.8 M | 533 K | 83.8 M | 82.3 M | 79.3 M | 467 K | 78 M | 77.2 M | 75.4 M | -118 M | 70.3 M | 59.5 M | 52.6 M | -82.9 M | 43.1 M | 42.6 M | 42.2 M | - | 41.5 M | 14 M | 2.99 M | - | 2.51 M | 2.27 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-23.6 M | -28.4 M | -26.6 M | -429 M | -26.9 M | -51.1 M | -72.2 M | -30.6 M | -31.2 M | -6.38 M | -25.2 M | -41.4 M | -33.2 M | -41.4 M | -26.3 M | -11.3 M | 2.12 M | -4.59 M | -5.35 M | -5.65 M | -13 M | -9.11 M | -9.81 M | -14.6 M | -37.3 M | -204 M | -78.8 M | -199 M | -25.5 M | -31.6 M | -46.7 M | -17.5 M | -12.4 M | -9.92 M | -13.6 M | -13.8 M | -12.6 M | -16.9 M | -18 M | -25.2 M | -11.2 M | -8.39 M | -123 M | -8.27 M | -12 M | 359 M | -11.3 M | -10.7 M | -25.2 M | -25.2 M | -5.44 M | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
725 M | 653 M | 496 M | 469 M | 480 M | 444 M | 484 M | 647 M | 621 M | 647 M | 640 M | 556 M | 511 M | 469 M | 428 M | 382 M | 353 M | 320 M | 297 M | 248 M | 222 M | 222 M | 215 M | 272 M | 265 M | 239 M | 247 M | 237 M | 220 M | 192 M | 198 M | 193 M | 150 M | 144 M | 140 M | 114 M | 108 M | 107 M | 106 M | - | -448 K | -14 K | - | - | - | -16.8 M | -11.3 M | - | -3.17 M | -5.94 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
637 M | 572 M | 412 M | 371 M | 380 M | 344 M | 381 M | 571 M | 541 M | 540 M | 536 M | 454 M | 387 M | 352 M | 310 M | 299 M | 267 M | 250 M | 220 M | 164 M | 163 M | 172 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
88.4 M | 80.8 M | 83.8 M | 97.3 M | 99.8 M | 100 M | 102 M | 75.7 M | 80.7 M | 107 M | 104 M | 102 M | 124 M | 117 M | 117 M | 83.1 M | 86 M | 70.2 M | 77.3 M | 83.9 M | 59.3 M | 49.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-6.19 M | -9.56 M | -10.6 M | -408 M | 886 K | -1.17 M | -1.62 M | -18.6 M | -16.3 M | 7.79 M | -13.4 M | -21.4 M | -17.9 M | -21.6 M | -10.4 M | -1.88 M | 13 M | -4.63 M | -2.8 M | -12.2 M | -6.58 M | -7.67 M | -15.9 M | 4.52 M | -16.4 M | -226 M | -25.1 M | -217 M | -20.1 M | -25.2 M | -46.6 M | -13.4 M | -11 M | -8.97 M | -14.1 M | -18.2 M | -14 M | -19.1 M | -21.5 M | -33.9 M | -15.8 M | -12.6 M | -175 M | - | -17.2 M | -11.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-298 K | 109 K | 742 K | 252 K | 80 K | -35 K | -48 K | 381 K | -43 K | -105 K | 8 K | -220 K | -77 K | -26 K | -220 K | -73 K | -345 K | 297 K | 178 K | -73 K | -41 K | -18 K | 6.34 M | -292 K | -110 K | 354 K | -70 K | -245 K | -84 K | -587 K | 427 K | 173 K | -124 K | 78 K | -18 K | 150 K | 15 K | 3 K | 2 K | -82 K | 255 K | 272 K | 279 K | - | - | 13 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
9.11 M | 5.74 M | 4.7 M | -369 M | 18.2 M | 15.6 M | 15.2 M | 3.3 M | 5.93 M | 29.8 M | 8.59 M | 750 K | 5.86 M | 2.43 M | 10.7 M | 9.02 M | 22.5 M | 2.67 M | 4.7 M | -4.91 M | 819 K | -471 K | -598 K | 11.9 M | -9.25 M | -217 M | -15.8 M | -208 M | -10.7 M | -15.6 M | -37.5 M | -4.15 M | -4.93 M | -2.97 M | -8.23 M | -10.4 M | -8.72 M | -14.2 M | -16.7 M | -29.3 M | -13.1 M | -10 M | -172 M | - | -13.2 M | -10.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
94.6 M | 90.4 M | 94.4 M | 505 M | 98.9 M | 102 M | 104 M | 94.3 M | 97 M | 99.1 M | 118 M | 577 M | 529 M | 491 M | 438 M | 384 M | 340 M | 325 M | 300 M | 261 M | 229 M | 230 M | 231 M | 247 M | 256 M | 443 M | 246 M | 451 M | 240 M | 217 M | 244 M | 206 M | 161 M | 153 M | 154 M | 132 M | 122 M | 126 M | 128 M | 122 M | 76 M | 69.1 M | 225 M | 60.2 M | 57.7 M | 22 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
73.1 M | 68.8 M | 72.8 M | 72.7 M | 77.6 M | 75.2 M | 78.4 M | 47.7 M | 67.1 M | 69.2 M | 79.1 M | 81.4 M | 96.6 M | 90.4 M | 89.7 M | 82.9 M | 68.5 M | 59 M | 58.9 M | 66.9 M | 51.3 M | 42.7 M | 58.6 M | 58.7 M | 52.4 M | 47.3 M | 52.1 M | 35.9 M | 58.8 M | 66.9 M | 74.8 M | 62.9 M | 59.6 M | 57.4 M | 55.5 M | 55.2 M | 45.8 M | 51.1 M | 53.6 M | 57.6 M | 38.4 M | 32.8 M | 31.9 M | - | 29.8 M | 13.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Evolent Health (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Teladoc Health
TDOC
|
$ 8.96 | -0.28 % | $ 1.58 B |  USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Phreesia
PHR
|
$ 13.15 | 1.94 % | $ 786 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 9.34 | -1.37 % | $ 173 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
10x Genomics
TXG
|
$ 62.88 | -3.34 % | $ 7.84 B | USA |
 |
Veeva Systems
VEEV
|
$ 306.1 | -0.1 % | $ 50.1 B | USA |
 |
SCWorx Corp.
WORX
|
$ 1.31 | -5.76 % | $ 9.53 M | USA |
 |
Zhongchao
ZCMD
|
$ 0.94 | -5.99 % | $ 3.21 M |  China |
 |
HealthStream
HSTM
|
$ 28.69 | -0.14 % | $ 861 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
So-Young International
SY
|
$ 2.0 | 0.5 % | $ 156 M | China |
 |
American Well Corporation
AMWL
|
$ 12.0 | -3.73 % | $ 193 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.54 | -3.01 % | $ 1.26 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.46 | -3.31 % | $ 102 M | USA |
 |
HealthEquity
HQY
|
$ 103.68 | 1.53 % | $ 8.93 B | USA |
 |
Omnicell
OMCL
|
$ 35.87 | -3.96 % | $ 1.65 B | USA |
 |
Progyny
PGNY
|
$ 36.44 | 1.35 % | $ 3.11 B | USA |
 |
Schrödinger
SDGR
|
$ 32.42 | -2.89 % | $ 2.38 B | USA |